• Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly adjusted loss of 81 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.35. The mean expectation of twelve analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -80 cents to -51 cents per share.

• Revenue rose 45.3% to $37.72 million from a year ago; analysts expected $40.31 million.

• Rhythm Pharmaceuticals Inc's reported EPS for the quarter was a loss of 81 cents​.

• The company reported a quarterly loss of $50.82 million.

• Rhythm Pharmaceuticals Inc shares had risen by 18.4% this quarter and gained 12.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $79.00

This summary was machine generated from LSEG data May 7 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)